Innovive Parmaceuticals has enrolled its first patients in a Phase I clinical trial of its investigational cancer vaccine Inno-105 in adult patients with advanced solid malignancies.
The objectives of the trial are to determine safety, dose, pharmacokinetic profile and preliminary efficacy of Inno-105. The treatment is derived from a naturally occurring peptide that inhibits cell growth and division by interacting with OGFr, a unique receptor found on the nuclear membrane of a wide range of malignant cells.
Preclinical studies have demonstrated antitumor activity in numerous tumor types. In addition, Inno-105 has recently demonstrated antitumor activity in a Phase I pancreatic cancer study. The new Phase I study will attempt to further increase the administered dose of Inno-105 and will expose the drug to a wider range of tumor types.